Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful faithfully but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be being used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire interview that I came away with an inadequate viewpoint of the company.

Irony of irony, my bad opinion of the business has grown steadily, however, the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your therapy as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the know-how and also linked intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) as well as the first brand new drug application approval ($five million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to get a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this individual remedy and a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active company with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications in addition to multiple presentations.

Might all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself through the very beginning of my interest in this particular business. Judging by way of the multiples of a huge number of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this particular question.

CytoDyn is a classic battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *